Table 1.
Patient characteristics
| mFOLFOX6 therapy (n = 136) | XELOX therapy (n = 104) | P value | |
|---|---|---|---|
| Age (years) | 66.0 (58.0–72.3) | 65.5 (55.8–70.0) | 0.067 |
| Sex (male, female) | 56, 80 | 51, 53 | 0.23 |
| Body surface area (m2) | 1.56 (1.42–1.69) | 1.59 (1.45–1.72) | 0.48 |
| Skin disease career (%) | 5.1 | 5.8 | 0.83 |
| History of allergy to platinum (%) | 27.9 | 28.8 | 0.88 |
| History of treatment with L-OHP (%) | 2.2 | 2.9 | 0.93 |
| Medical history with L-OHP(%) | 20.6 | 21.2 | 0.91 |
| Stage (%) | |||
| 1 | 0 | 0 | 0.32 |
| 2 | 2.9 | 2.9 | |
| 3 | 17.6 | 27.9 | |
| 4 | 79.4 | 69.2 | |
| Metastasis (%) | 79.4 | 69.2 | 0.071 |
| L-OHP | |||
| By infusion port (%) | 100 | 26.0 | <0.001 |
| Dosage (mg/m2/cycle) | 82.2 (77.2–84.5) | 123.0 (109.4–127.0) | <0.001 |
| Cumulative dosage (mg/m2) | 609.1 (417.1–919.1) | 651.3 (454.4–942.1) | 0.55 |
| Cumulative dosage (mg) | 915.0 (627.5–1469.5) | 1000.0 (625.2–1502.9) | 0.60 |
| Monoclonal antibody | |||
| Bmab (%) | 42.6 | 41.3 | 0.92 |
| Pmab (%) | 11.0 | 0 | 0.001 |
| Steroid | |||
| Dex dosage (mg/cycle) | 8.06 ± 0.72 | 7.93 ± 0.44 | 0.17 |
| Co-administration with L-OHP (%) | 0 | 74.0 | 0.001 |
| Pre-medication with steroid except Dex (%) | 10.3 | 16.3 | 0.17 |
| Laboratory data | |||
| Albumin (g/dL) | 3.8(3.2–4.1) | 4.0 (3.7–4.3) | 0.002 |
| AST (IU/L) | 23.0 (17.8–34.0) | 21.0 (17.0–28.0) | 0.047 |
| ALT (IU/L) | 19.0 (12.0–30.0) | 17.5 (12.0–26.0) | 0.50 |
| Scr (mg/dL) | 0.70 (0.61–0.88) | 0.71 (0.58–0.83) | 0.45 |
| eGFR (mL/min/1.73 m2) | 75.2 (63.0–89.4) | 78.2 (66.2–93.1) | 0.30 |
L-OHP oxaliplatin, Bmab bevacizumab, Pmab panitumumab, Dex dexamethasone, ASL aspartate aminotransferase, ALT alanine aminotransferase, Scr serum creatinine, eGFR estimate glomerular filtration rate